Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T39113L |
Povorcitinib phosphate
|
JAK | Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells |
Povorcitinib phosphate 是一种选择性 JAK1 抑制剂,可用于治疗皮肤红斑狼疮和扁平苔藓的研究。 | |||
T77491 |
Prezalumab
AMG 557 |
Others | Others |
Prezalumab (AMG 557) 是一种针对 ICOSL 和 BAFF 的人源 IgG2 单克隆抗体。Prezalumab 可用于研究干燥综合征皮肤红斑狼疮、银屑病、系统性红斑狼疮关节炎和系统性红斑狼疮 (SLE)。 | |||
T39113 |
Povorcitinib
|
||
Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP). | |||
T70930 |
GSK SYK inhibitor
|
||
The immunoregulator spleen tyrosine kinase (SYK) is upregulated in cutaneous lupus erythematosus (CLE). This double-blind, multicentre, Phase Ib study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of the selective SYK inhibitor GSK2646264 in active CLE lesions | |||
T63284 |
PAD-IN-2
|
||
PAD-IN-2 是 pad4 的有效抑制剂,IC50 值 <1 μM,能够用于研究自身免疫性疾病和癌症,如类风湿性关节炎、血管炎、系统性红斑狼疮、皮肤红斑狼疮、囊性纤维化、溃疡性结肠炎、哮喘、多发性硬化和牛皮癣。 | |||
T78329 |
Litifilimab
BIIB059 |
||
Litifilimab为一种靶向C型凝集素结构域家族4成员C(CLEC4C)的人源化IgG1-κ抗体,主要用于皮肤红斑狼疮(CLE)研究。 |